Introduction
============

Advances in our understanding of the pathophysiology of CINV, identification of patient risk factors \[[@mdx698-B1], [@mdx698-B2]\], and development of new antiemetics have led to dramatic improvements in prevention of chemotherapy-induced nausea and vomiting (CINV) \[[@mdx698-B3], [@mdx698-B4]\]. With utilization of guideline-recommended antiemetic prophylaxis, CINV can now be prevented in the majority of patients \[[@mdx698-B5], [@mdx698-B6]\]. As a result, the quality-of-life of cancer patients has significantly improved and patients may avoid chemotherapy disruption or dose reductions \[[@mdx698-B3]\].

Evidence-based antiemetic guidelines \[[@mdx698-B7]\] for patients receiving highly emetogenic chemotherapy (HEC) consistently recommend co-administration of a triplet antiemetic regimen of a 5-hydroxytryptamine-3 (5-HT~3~) receptor antagonist (RA), a neurokinin-1 (NK~1~) RA and a corticosteroid, such as dexamethasone (DEX). The American Society of Clinical Oncology (ASCO) has also recently recommended the addition of olanzapine to this triplet regimen \[[@mdx698-B7]\].

Despite evidence demonstrating that CINV control is optimized when guideline recommendations are followed \[[@mdx698-B5], [@mdx698-B6]\], guidelines are often inadequately adhered to in clinical practice. This may, in part, be due to perceived complexity of some of the multimodal antiemetic regimens, as the NK~1~RAs, 5-HT~3~RAs, and corticosteroid components each have differing doses/schedules from 1 to 4 days post-chemotherapy initiation. Simpler, less frequent dosing regimens have been shown to result in better compliance across a variety of therapeutic classes \[[@mdx698-B10]\].

NEPA was developed as an oral fixed combination of the highly selective NK~1~RA, netupitant (300 mg), and the clinically \[[@mdx698-B4]\] and pharmacologically \[[@mdx698-B11]\] distinct 5-HT~3~RA, palonosetron (0.5 mg). The simultaneous targeting of two critical antiemetic pathways, in unison with the single dose administration results in a convenient antiemetic offering long-lasting protection from CINV.

Pivotal clinical studies have demonstrated superiority of oral NEPA plus DEX over oral palonosetron plus DEX in preventing CINV during the acute (0--24 h), delayed (25--120 h), and overall (0--120 h) phases following both cisplatin- \[[@mdx698-B12]\] and anthracycline--cyclophosphamide (AC)-based chemotherapy \[[@mdx698-B13], [@mdx698-B14]\]. In addition, NEPA was shown to be efficacious over multiple cycles in patients receiving either HEC or moderately emetogenic chemotherapy (MEC) \[[@mdx698-B15]\].

These studies supported the registration of oral NEPA in the United States (US) and Europe (EU) \[[@mdx698-B16], [@mdx698-B17]\], with NEPA becoming the first alternative NK~1~RA (containing compound) and the first antiemetic fixed combination. Subsequently, the next NK~1~RA, oral rolapitant, was approved \[[@mdx698-B18]\]. An intravenous fixed combination of NEPA (fosnetupitant 235 mg and palonosetron 0.25 mg) is currently under evaluation by the US Food & Drug Administration (FDA). Thus far, none of the NK~1~RAs have been compared in head-to-head trials, as all registration studies were conducted with a 5-HT~3~RA/DEX comparative control.

Herein we report the results of a Phase III study of a single dose of NEPA plus DEX compared with a standard 3-day regimen of aprepitant plus granisetron (APR/GRAN) plus DEX, in patients receiving cisplatin-based chemotherapy. The objective was to demonstrate, in the first head-to head comparison study, non-inferiority of NEPA to APR/GRAN in preventing CINV associated with HEC. The study was designed in collaboration with the China FDA (CFDA) as a registration study for oral NEPA in China.

Patients and methods
====================

Study design
------------

This was a phase III, multicenter, randomized, double-blind/double-dummy, single initial cycle, parallel group international study. Patients were randomized at 46 enrolling sites in 4 countries (30 in China, 5 Taiwan, 3 Thailand, and 8 Korea) between February 2014 and August 2015.

The trial protocol was approved by institutional review board/independent ethics committees and all patients provided written informed consent before treatment initiation. The study was conducted in compliance with the Code of Ethics for the CFDA, Good Clinical Practice, the principles of the Declaration of Helsinki and the International Conference on Harmonization guidelines.

Patients
--------

Inclusion/exclusion criteria were similar to those in the original oral NEPA pivotal trials \[[@mdx698-B12], [@mdx698-B13], [@mdx698-B15]\]. Eligible patients were ≥18 years, naïve to chemotherapy, and scheduled to receive their first course of cisplatin-based (≥50 mg/m^2^) chemotherapy (as monotherapy or in combination with other chemotherapy) for the treatment of a confirmed solid tumor malignancy. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0--2.

Patients were not eligible if they were scheduled to receive: (i) MEC or HEC from days 2 to 5 following cisplatin, (ii) moderately or highly emetogenic radiotherapy within 1 week before day 1 or between days 1 and 5, or (iii) a bone marrow or stem-cell transplant. Additional exclusion criteria included: receipt of medication with antiemetic effect \<24 h of day 1; vomiting, retching or mild nausea \<24 h before day 1; serious cardiovascular disease history or predisposition to cardiac conduction abnormalities except for incomplete right bundle branch block; or chronic use of select CYP3A4 inducers \<4 weeks or a substrate or inhibitor \<1 week before day 1.

Treatment
---------

Patients were stratified by gender and randomly assigned (1 : 1) to receive either NEPA or APR/GRAN treatment ([supplementary Table S1](#sup2){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Granisetron 3 mg is the registered dose in China.

**Group 1:**

 Day 1: NEPA (300 mg netupitant and 0.5 mg palonosetron) plus DEX 12 mg

Days 2--4: DEX 8 mg daily

**Group 2:**

 Day 1: aprepitant 125 mg plus 3 mg IV granisetron plus DEX 12 mg

Days 2--4: aprepitant 80 mg daily (days 2--3) plus DEX 8 mg daily (days 2--4)

Assessments
-----------

During days 1--5 (0--120 h), each patient completed a diary, capturing emetic episodes, severity of nausea and rescue medications intake. An emetic episode was defined as any episode of vomiting or retching or combined vomiting/retching. Severity of nausea was evaluated using a 100-mm horizontal visual analog scale (VAS) ranging from 'no nausea' (0 mm) to 'nausea as bad as it could be' (100 mm). The Functional Living Index-Emesis (FLIE) questionnaire \[nine nausea-specific (nausea domain) and nine vomiting-specific (vomiting domain) items\] was used to assess the impact of CINV on patient's daily life. Responses were marked on a 100-mm VAS with anchors of 1 and 7. Patients completed this questionnaire on days 2 and 6 \[[@mdx698-B19]\]. The proportion of patients with scores reflecting 'no impact on daily life' (NIDL) (i.e. individual question scores \>6 on the 7-point FLIE scale, domain score \>54, overall FLIE score \>108) was evaluated.

The primary efficacy endpoint was complete response (CR: no emesis, no rescue medication) during the overall phase. Key secondary efficacy endpoints included CR during the acute/delayed phases and each individual day, and no emesis, no significant nausea (NSN : VAS score \<25 mm), no nausea (VAS score \< 5 mm), and no rescue medication during the acute, delayed and overall phases. FLIE scores reflecting NIDL during the acute/delayed phases were also evaluated as a secondary 'quality-of-life' endpoint.

Safety was assessed by collection of adverse events, vital signs, physical examination, clinical laboratory tests, and electrocardiograms (predose, and 5, 24, and 120 postdose).

Statistical analysis
--------------------

For the primary endpoint, non-inferiority of NEPA and APR/GRAN was demonstrated if the lower limit of the confidence interval (CI; two-sided 95% CI significance level) for the difference between NEPA and APR/GRAN in proportion of patients with overall CR was greater than −10%. The risk difference and associated 95% CI were analyzed using the Cochran--Mantel--Haenszel (CMH) test stratified by gender. For secondary endpoints of acute/delayed and daily CR as well as no emesis, NSN, no nausea, no rescue use, and NIDL as assessed by the FLIE, statistical analyses utilized the same methods as the primary endpoint, without testing for non-inferiority.

The sample size was based on the assumption of an overall CR rate of 75% in both treatment groups. For a two-sided test of difference using a Type I error of 0.05, a sample size of 395 assessable patients/group was needed to ensure 90% power. Assuming a drop-out rate of 5%, this was increased to 416 patients/group for a total of 832 patients.

The number and proportion of patients who experienced treatment-emergent adverse events (AEs) and treatment-related adverse events (TRAEs) was listed and summarized by treatment group. The full analysis set (FAS) population (efficacy analyses) was defined as all patients who were randomized and received protocol-required cisplatin and study treatment. The safety analysis population consisted of all patients who received study treatment.

Results
=======

Analyzed patient population
---------------------------

A total of 834 patients were randomized into the study (*N* = 417/group); 81% of patients were from China, and 12% from Thailand. Four patients randomized to NEPA and one patient to APR/GRAN did not receive study treatment and were therefore excluded from the safety/FAS populations. One additional NEPA-treated patient did not receive the protocol-required HEC and was also excluded from the FAS population. Consequently, 829 (413 NEPA/416 APR/GRAN) and 828 (412 NEPA/416 APR/GRAN) represented the safety and FAS efficacy populations, respectively ([supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

Baseline characteristics were similar between treatment groups (Table [1](#mdx698-T1){ref-type="table"}). The population was predominantly males (71%); lung cancer was the most common (58%) cancer type. Table 1.Patient baseline and disease characteristics (safety population)Characteristic**NEPA + DEX** (***N* = 413)APR/GRAN +  DEX** (***N**** *= 416)**Overall** (*N* = 829)Gender Male292 (70.7%)297 (71.4%)589 (71.0%) Female121 (29.3%)119 (28.6%)240 (29.0%)Age (years), mean (SD)54.6 (9.63)54.5 (10.24)54.6 (9.93)Race Asian413 (100.0%)416 (100.0%)829 (100.0%)BSA (m^2^), mean (SD)1.67 (0.159)1.68 (0.158)1.67 (0.158)BMI (kg/m^2^), mean (SD)22.49 (3.337)22.85 (3.435)22.67 (3.389)ECOG performance status 0175 (42.5%)171 (41.1%)346 (41.8%) 1231 (56.1%)236 (56.7%)467 (56.4%) 27 (1.7%)9 (2.2%)16 (1.9%)Most common (≥5%) cancer types Lung254 (61.5%)229 (55.0%)483 (58.3%) Head and neck24 (5.8%)31 (7.5%)55 (6.6%)Cisplatin[^a^](#tblfn1){ref-type="table-fn"}412 (99.8%)416 (100%)828 (99.9%) Dose \<70 mg/m^2^161 (39.0%)177 (42.5%)338 (40.8%) Dose ≥70 mg/m^2^251 (60.8%)239 (57.5%)490 (59.1%)Most common (≥5%) concomitant chemotherapy Gemcitabine123 (29.8%)93 (22.4%)216 (26.1%) Pemetrexed69 (16.7%)79 (19.0%)148 (17.9%) Docetaxel67 (16.2%)68 (16.3%)135 (16.3%) Etoposide58 (14.0%)53 (12.7%)111 (13.4%) Fluorouracil27 (6.5%)32 (7.7%)59 (7.1%)[^1][^2]

Efficacy
--------

For the primary efficacy endpoint, NEPA demonstrated non-inferiority to APR/GRAN with overall CR rates of 73.8% and 72.4%, respectively (95% CI: −4.5%, 7.5%) (Figure [1](#mdx698-F1){ref-type="fig"}).

![Complete response rates.](mdx698f1){#mdx698-F1}

Daily rates of patients with CINV events (experiencing emesis and/or use of rescue medication) remained between 13% and 15% for APR/GRAN and declined from 16% to 8% over the 5 days for NEPA. The difference between treatment groups (8.0% NEPA and 13.9% APR/GRAN, 95% CI: 1.7%, 10.2%) reached statistical significance on day 5 (Figure [2](#mdx698-F2){ref-type="fig"}**)**.
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Response rates for the secondary efficacy endpoints during the acute phase slightly favored NEPA with the exception of no emesis, where slightly higher rates were seen for APR/GRAN (Table [2](#mdx698-T2){ref-type="table"}). During the delayed and overall phases response rates favored NEPA for no emesis, NSN, and no rescue use, while no nausea rates were slightly higher for APR/GRAN. No rescue medication rates were significantly higher for NEPA during the delayed and overall phases (Table [2](#mdx698-T2){ref-type="table"}). Metoclopramide was the most common rescue medication, used by 2.7% of NEPA patients and 5.0% of APR/GRAN patients, while all other rescue medications were used by \<1% of patients. Table 2.Secondary endpoints: no emesis, no significant nausea, and no rescue medication ratesEndpoint % patients**NEPA + DEX**(***N *= 412)APR/GRAN +  DEX** (***N *= 416)Risk difference**(**95% CI)**No emesis   Acute85.2%87.5%−2.2% (−6.9%, 2.4%)   Delayed79.4%76.2%3.3% (−2.4%, 8.9%)   Overall75.0%74.0%1.1% (−4.8%, 6.9%)NSN   Acute89.8%87.3%2.6% (−1.7%, 6.9%)   Delayed78.2%72.8%5.4% (−0.4%, 11.2%)   Overall75.7%70.4%5.4% (−0.6%, 11.4%)No nausea   Acute68.9%67.8%1.2% (−5.1%, 7.5%)   Delayed53.2%54.3%−1.1% (−7.9%, 5.7%)   Overall49.3%51.4%−2.1% (−8.9%, 4.7%)No rescue use   Acute98.8%98.3%0.5% (−1.2%, 2.1%)   Delayed97.6%94.7%2.9% (0.2%, 5.5%)[\*](#tblfn3){ref-type="table-fn"}   Overall96.6%93.5%3.1% (0.2%, 6.1%)[\*](#tblfn3){ref-type="table-fn"}[^3][^4]

A higher proportion of NEPA-treated patients reported NIDL due to nausea (nausea domain), vomiting (vomiting domain), or both (overall domain) during the acute and delayed phases; this was significant for the nausea domain during the delayed phase (Figure [3](#mdx698-F3){ref-type="fig"}).

![Proportion of patients with no impact on daily living (NIDL) based on the functional living index-emesis (FLIE).](mdx698f3){#mdx698-F3}

Safety
------

The incidence of AEs was comparable between the two treatment groups (NEPA 58.1%, APR/GRAN 57.5%). The most common TRAEs were constipation (NEPA 8.0%, APR/GRAN 6.3%) and hiccups (NEPA 2.7%, APR/GRAN 1.4%). Among the patients reporting AEs, the majority (90%) reported events of mild/moderate intensity, with more severe AEs in the APR/GRAN group (10.8% versus NEPA 8.7%). There were two patients with serious TRAEs in each group (NEPA: i) atrial fibrillation and (ii) chest pain/hypotension/decreased heart rate/non-responsiveness (concomitant medication included amifostine); APR/GRAN: (i) increased alanine aminotransferase and (ii) pancreatitis. While the patient experiencing the chest pain/hypotension event recovered within an hour of NEPA treatment, this was the only AE leading to discontinuation from study. There were no deaths in the NEPA group, while four patients treated with APR/GRAN died due to unrelated AEs. Changes from baseline in 12-lead ECGs were rare and similar.

Discussion
==========

While the current antiemetic armamentarium offers the potential to prevent CINV in the majority of patients, events including hospitalization do occur. Simplifying the multi-drug regimens may be appealing to clinicians and patients and may enhance compliance with antiemetic guideline recommendations. The standard aprepitant regimen requires co-administration of a 5-HT~3~ RA (in this study IV GRAN 30 min before chemotherapy) on day 1 and oral APR 60 min before chemotherapy on day 1 with subsequent oral doses 24 and 48 h later. As a combination of a highly selective NK~1~RA, netupitant, and the clinically superior 5-HT~3~RA, palonosetron, NEPA conveniently packages two classes of antiemetics recommended by guidelines in the HEC/high risk MEC settings in a single oral dose administered 60 min before chemotherapy. In clinical practice NEPA could either be taken at home or at the clinic/hospital before chemotherapy.

Aprepitant, the first NK~1~RA in the class has been long available with well-established efficacy and safety in various HEC and MEC settings including cisplatin-, carboplatin-, and AC-based chemotherapies \[[@mdx698-B20]\]. Similarly, NEPA/DEX demonstrated unequivocal superiority over palonosetron/DEX in preventing CINV in pivotal trials in the HEC/AC settings, leading to its approval in the USA/Europe \[[@mdx698-B12], [@mdx698-B13], [@mdx698-B15]\]. With the most recent approval of rolapitant, the third-in-class NK~1~RA, clinicians have three NK~1~RA-containing options for patients at most risk for CINV. Recently, a network meta-analysis showed that all three NK~1~RAs have similar antiemetic effects \[[@mdx698-B21]\]. However, thus far, no NK~1~-containing regimens have been directly compared with each other.

For NEPA registration in China, the CFDA requested that NEPA demonstrate comparable efficacy to a standard aprepitant and 5-HT~3~RA (granisetron) containing regimen. Thus, this phase III study in patients receiving cisplatin-based HEC was designed to demonstrate non-inferiority of a single dose of NEPA to a standard 3-day aprepitant/granisetron regimen, both groups in combination with DEX as recommended by antiemetic guidelines. This study was also the first head-to-head comparison study of NK~1~-containing regimens. For the primary efficacy endpoint of overall CR, NEPA was non-inferior to APR/GRAN. For secondary efficacy endpoints of no emesis and NSN, delayed and overall rates were numerically but not significantly higher for NEPA. In addition, significantly more patients treated with NEPA did not need to use any rescue medication during the delayed and overall phases. Daily rates of CINV events (emesis/rescue use) did not change substantially throughout days 1--5 for APR/GRAN; however, rates for NEPA declined numerically over time and were significantly lower on day 5, again suggesting a benefit for delayed CINV.

The slightly higher response rates for NEPA were reflected in a quality of life benefit, with a correspondingly greater proportion of patients with no impact on their functioning due to nausea during the delayed phase, when CINV control is most challenging. While this difference is small, it is encouraging that NEPA demonstrated some potential to improve quality of life.

The efficacy findings seen in the current study were consistent with those in two NEPA registration trials \[[@mdx698-B12], [@mdx698-B15]\] where NEPA, although not statistically compared, was shown to be at least as effective as an exploratory APR/ondansetron regimen \[[@mdx698-B12]\] and an exploratory APR/palonosetron regimen \[[@mdx698-B15]\].

NEPA was well tolerated with a comparable adverse event profile to APR/GRAN. The majority of AEs were mild/moderate in intensity, unrelated to study treatment, and typical for a cancer population undergoing chemotherapy. There were no cardiac safety concerns for either treatment.

A limitation of this study was the predominance of male patients, with females representing only 29% of the study population. Gender is a well-established risk factor, with females at greater risk for CINV. In two recent identically designed rolapitant trials, the difference in proportions of males/females in the studies was deemed as a potential factor that may have contributed to differing antiemetic efficacy in the studies \[[@mdx698-B22]\]. As gender was balanced for the NEPA and APR/GRAN groups within this study, this should not have influenced these results.

As the majority of the patients in the NEPA pivotal trials were Caucasian, this study raises the question as to whether similar antiemetic efficacy would be seen in Asian and Caucasian populations. Additional studies would be needed to determine this; however, it is reassuring that a comparison of the pharmacokinetic profiles of netupitant and palonosetron in Chinese and Caucasian patients show differences considered as not clinically meaningful \[[@mdx698-B23]\].

In conclusion, our study indicated that as a combination antiemetic targeting two antiemetic pathways with a single dose administered only once per cycle, NEPA offers a convenient and simplified prophylactic antiemetic that is at least as effective as a 3-day aprepitant regimen with granisetron.
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[^1]: Median cisplatin dose was 73 mg/m^2^ in the NEPA group and 72 mg/m^2^ in the APR/GRAN group.

[^2]: APR, aprepitant; GRAN, granisetron; SD, standard deviation; BSA, body surface area; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group.

[^3]: *P* \< 0.05, based on CMH test with gender as stratifying variable.

[^4]: APR, aprepitant; GRAN, granisetron; DEX, dexamethasone; NSN, no significant nausea.
